Select Page

CircuLex CML-HSA/Nε-(Carboxymethyl)lysine-HSA

CY-R2066
Recombinant Protein
200 μg

$275.63

DATA SHEET

CircuLex CML-HSA/Nε-(Carboxymethyl)lysine-HSA of 200 µg.

TargetCML-HSA/Nε-(Carboxymethyl)lysine
Product TypeRecombinant Protein
FormulationThe CML-HSA /Nε-(carboxymethyl) lysine-HSA is supplied frozen in a buffer containing 10mM PBS (pH 7.2).
Research AreaMetabolism
Description/BackgroundReducing sugars react with protein amino groups to form a diverse group of protein-bound moieties with fluorescent and cross-linking properties. These compounds, called advanced glycosylation end products (AGEs), have been implicated in the structural and functional alterations of proteins that occur during aging and long-term diabetes. Although several AGE structures have been reported (1, 2), it was demonstrated that Nε -(Carboxymethyl)lysine (CML) is a major antigenic AGE structure. CML concentration is also increased in patients who have diabetes with complications, including nephropathy (3–5), retinopathy (6), and atherosclerosis (7–9). CML is also recognized by receptor for AGE (RAGE), and CML-RAGE interaction activates cell signaling pathways such as NF-B and enhances the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells (10).
Storage Temperature-20°C
Concentration1.0 mg/mL
Regulatory StatementFor Research Use Only. Not for use in diagnostic procedures.
CY-R2066
Recombinant Protein
200 μg

$275.63

Related Products

Related Content

SIGN UP